(VIANEWS) – Coda Octopus Group (CODA), Esquire Financial Holdings (ESQ), NICE Ltd (NICE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Coda Octopus Group (CODA)
43.9% sales growth and 5.84% return on equity
Coda Octopus Group, Inc., together with its subsidiaries, develops, sells, and rentals underwater technologies and equipment for real time 3D imaging, mapping, defense, and survey applications in the United States of America and internationally. The company operates through two segments, Marine Engineering Business and Marine Technology Business. It sells technology solutions to the subsea and underwater markets. The company's solutions include geophysical systems, a geophysical data acquisition systems, processing, and analysis software that are used primarily by survey companies, offshore renewable companies, research institutions, and salvage companies; GNSS-aided navigation systems (attitude and positioning systems); Real time volumetric imaging sonar; and diver augmented vision display system. It offers CodaOctopus GeoSurvey products, such as hardware and software solutions for field acquisition of sidescan sonar and sub-bottom profiler; and CodaOctopus DA4G productivity suite of software that automates the tasks of analyzing, annotating, and mosaicing complex data sets. It markets its products under the CodaOctopus brand name. Coda Octopus Group, Inc. was founded in 1994 and is headquartered in Orlando, Florida.
Earnings Per Share
As for profitability, Coda Octopus Group has a trailing twelve months EPS of $0.26.
PE Ratio
Coda Octopus Group has a trailing twelve months price to earnings ratio of 27.92. Meaning, the purchaser of the share is investing $27.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.84%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12%, now sitting on 18.82M for the twelve trailing months.
Yearly Top and Bottom Value
Coda Octopus Group’s stock is valued at $7.26 at 01:22 EST, under its 52-week high of $7.83 and way higher than its 52-week low of $5.21.
Sales Growth
Coda Octopus Group’s sales growth is 47.9% for the ongoing quarter and 43.9% for the next.
Moving Average
Coda Octopus Group’s value is above its 50-day moving average of $7.09 and way above its 200-day moving average of $6.36.
2. Esquire Financial Holdings (ESQ)
16.1% sales growth and 20.32% return on equity
Esquire Financial Holdings, Inc. operates as the bank holding company for Esquire Bank, National Association that provides commercial banking products and services to legal industry and small businesses, and commercial and retail customers in the United States. The company offers checking, savings, money market, and time deposits, as well as certificates of deposit. It also provides commercial loans, including short-term financing for inventory, receivables, the purchase of supplies, or other operating needs arising during the normal course of business, as well as loans to its qualified merchant customers; commercial lines of credit; consumer loans consisting of post-settlement consumer and structured settlement loans to plaintiffs and claimants, as well as loans to individuals for debt consolidation, medical expenses, living expenses, payment of outstanding bills, or other consumer needs; and real estate loans, such as multifamily, 1-4 family residential, commercial real estate, and construction loans, as well as merchant services. As of December 31, 2020, the company operated a full-service branch in Jericho, New York; and an administrative office in Boca Raton, Florida. Esquire Financial Holdings, Inc. was founded in 2006 and is headquartered in Jericho, New York.
Earnings Per Share
As for profitability, Esquire Financial Holdings has a trailing twelve months EPS of $4.79.
PE Ratio
Esquire Financial Holdings has a trailing twelve months price to earnings ratio of 12.43. Meaning, the purchaser of the share is investing $12.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.32%.
Sales Growth
Esquire Financial Holdings’s sales growth is 16.3% for the ongoing quarter and 16.1% for the next.
Moving Average
Esquire Financial Holdings’s value is higher than its 50-day moving average of $55.50 and way higher than its 200-day moving average of $49.86.
3. NICE Ltd (NICE)
15.7% sales growth and 11.89% return on equity
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for the customer engagement market; and smart self service enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing. The company provides smart self service solutions that empower organizations to build intelligent automated conversations based on data; and prepared agent solutions and tools enable contact center agents to guide and alert them in real time; provides solutions that help organizations to record structured and unstructured customer interaction and transaction data; and NICE Evidencentral, an digital evidence management platform for public safety emergency communications, law enforcement, and criminal justice helps agencies. In addition, it offers X-Sight, is an open and flexible AI-cloud platform for financial crime and compliance; Xceed, a cloud platform for comprehensive AML and fraud prevention for small and mid-sized organizations; data intelligence solutions that enable organizations to turn raw data into comprehensive actionable intelligence to prevent and detect financial crimes; AI and analytics technologies to detect and prevent financial crimes in real-time; money laundering and fraud prevention solutions that help organizations adhere to capital markets compliance and anti-money laundering compliance regulations; intelligent investigations solutions; and self-service solutions that provide organizations with customization and self-development capabilities. The company was formerly known as NICE-Systems Ltd. and changed its name to NICE Ltd. in June 2016. NICE Ltd. was founded in 1986 and is headquartered in Ra'anana, Israel.
Earnings Per Share
As for profitability, NICE Ltd has a trailing twelve months EPS of $5.11.
PE Ratio
NICE Ltd has a trailing twelve months price to earnings ratio of 45.4. Meaning, the purchaser of the share is investing $45.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.89%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.3%, now sitting on 2.55B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 18.1% and 19.9%, respectively.
Sales Growth
NICE Ltd’s sales growth is 13.7% for the current quarter and 15.7% for the next.
Volume
Today’s last reported volume for NICE Ltd is 491577 which is 34.44% above its average volume of 365622.
4. Materialise NV (MTLS)
14.2% sales growth and 4.59% return on equity
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. It operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Earnings Per Share
As for profitability, Materialise NV has a trailing twelve months EPS of $0.21.
PE Ratio
Materialise NV has a trailing twelve months price to earnings ratio of 24.52. Meaning, the purchaser of the share is investing $24.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.59%.
Moving Average
Materialise NV’s worth is under its 50-day moving average of $5.43 and under its 200-day moving average of $5.48.
Volume
Today’s last reported volume for Materialise NV is 85534 which is 34.08% below its average volume of 129760.
Yearly Top and Bottom Value
Materialise NV’s stock is valued at $5.15 at 01:22 EST, way below its 52-week high of $6.93 and higher than its 52-week low of $4.70.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.2%, now sitting on 257.86M for the twelve trailing months.
5. ACADIA Pharmaceuticals (ACAD)
10.6% sales growth and 6.7% return on equity
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ACADIA Pharmaceuticals has a trailing twelve months EPS of $0.19.
PE Ratio
ACADIA Pharmaceuticals has a trailing twelve months price to earnings ratio of 85.89. Meaning, the purchaser of the share is investing $85.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.7%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 135% and a drop 67.9% for the next.
6. Option Care Health (OPCH)
10.5% sales growth and 14.64% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $1.2.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 26.75. Meaning, the purchaser of the share is investing $26.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.64%.
Sales Growth
Option Care Health’s sales growth is 11% for the current quarter and 10.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 4.59B for the twelve trailing months.
